Cargando…
Selective pressure of endocrine therapy activates the integrated stress response through NFκB signaling in a subpopulation of ER positive breast cancer cells
BACKGROUND: While estrogen receptor (ER) positive breast tumors generally respond well to endocrine therapy (ET), up to 40% of patients will experience relapse, either while on endocrine therapy or after ET is completed. We previously demonstrated that the selective pressure of tamoxifen activates t...
Autores principales: | Semina, Svetlana E., Pal, Purab, Kansara, Nidhi S., Huggins, Rosemary J., Alarid, Elaine T., Greene, Geoffrey L., Frasor, Jonna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908626/ https://www.ncbi.nlm.nih.gov/pubmed/35264224 http://dx.doi.org/10.1186/s13058-022-01515-1 |
Ejemplares similares
-
Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer Cells
por: Pal, Purab, et al.
Publicado: (2022) -
Identification of a novel ER-NFĸB-driven stem-like cell population associated with relapse of ER+ breast tumors
por: Semina, Svetlana E., et al.
Publicado: (2022) -
Estrogen Receptor-Regulated Gene Signatures in Invasive Breast Cancer Cells and Aggressive Breast Tumors
por: Smart, Emily, et al.
Publicado: (2022) -
PHLDA1 Expression is Controlled by an Estrogen Receptor (ER)-NFκB-miR-181 Regulatory Loop and is Essential for Formation of ER+ Mammospheres
por: Kastrati, Irida, et al.
Publicado: (2014) -
Emerging Roles of Ceramides in Breast Cancer Biology and Therapy
por: Pal, Purab, et al.
Publicado: (2022)